Bylavy
| Chemical Name | odevixibat |
| Dosage Form | Pellet (oral; 200 mcg, 600 mcg); Capsule (oral; 400 mcg, 1200 mcg) |
| Drug Class | Ileal bile acid transporter inhibitors |
| System | Digestive |
| Company | Albireo |
| Approval Year | 2021 |
Indication
- For the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).